抗精神病薬の世界市場規模調査＆予測、疾患別、薬剤クラス別、流通チャネル別、地域別分析、2023年～2030年

抗精神病薬の世界市場は、2022年に約154億7,000万米ドルと評価され、予測期間2023年～2030年には6％以上の成長率で成長すると予測されています。

抗精神病薬は、統合失調症や双極性障害などの精神病性障害の症状を管理するために使用される薬です。抗精神病薬は、脳内の神経伝達物質、特にドーパミンとセロトニンの活性を変化させることによって作用します。第一世代（定型）と第二世代（非定型）の抗精神病薬です。クロルプロマジンなどの第一世代抗精神病薬は主にドパミン受容体を遮断するが、リスペリドンなどの第二世代抗精神病薬はドパミン受容体とセロトニン受容体の両方に作用します。第二世代の抗精神病薬は、運動障害のリスクが低いため、好んで使用されます。これらの薬剤は、症状の重篤度と個々の反応に基づいて処方され、副作用を管理するために綿密なモニタリングが行われます。精神障害の急増、高齢者層の拡大、非定型抗精神病薬への嗜好の変化、メンタルヘルスに焦点を当てた啓発プログラムの高まりは、総じて世界中の抗精神病薬市場の拡大に拍車をかけています。さらに、偏見をなくし人権を促進することを目的とした教育やアドボカシー活動への重点が高まっていることも、世界の抗精神病薬市場の成長をさらに後押ししています。

さらに、精神疾患の有病率の増加が世界の市場拡大を促進します。

このような世界の患者数の急増は、市場の成長を大きく促進すると予想されます。例えば、世界保健機関（WHO）が発表した2022年の論文では、精神障害は2030年までに世界経済に推定6兆米ドルの負担を課す可能性があると予測されています。このような統計は、精神疾患の深刻さに対する認識が高まり続けていることから、これらの治療薬に対する需要を刺激すると予想されます。2022年のWHOの推計によると、2019年には全世界で約9億7,000万人、つまり約8人に1人が不安やうつなどの精神障害を抱えているといいます。しかし近年、統合失調症や双極性障害の有病率が上昇しています。その結果、複数の製薬会社がこの領域での研究開発努力を強化し、予測期間における新製品のイントロダクションつながっています。これらの要因により、今後数年間は世界市場の大幅な成長が見込まれます。さらに、長時間作用型注射剤（LAI）の採用増加や、新規抗精神病薬開発のための研究開発イニシアチブの高まりは、予測期間中に様々な有利な機会をもたらします。しかし、抗精神病薬に関連するいくつかの副作用と精神保健プログラムのコスト上昇が、2023-2030年の予測期間を通じて市場成長の妨げとなっています。

抗精神病薬の世界市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、精神疾患の有病率が高く、大手バイオ医薬品企業が存在するため、2022年の市場シェアは最大で、市場を独占しました。全米精神疾患連合（NAMI）の2022年版報告書によると、米国における双極性障害の年間有病率は2.8％で、推定700万人が罹患しています。さらに、同地域では技術的に進歩した抗精神病薬の採用が進んでおり、市場の地位向上に大きく貢献しています。さらに、精神疾患の深刻さを強調する啓発キャンペーンが活発であることから、予測期間を通じて北米の市場成長はさらに促進されると予想されます。一方、アジア太平洋地域は予測期間中に最も急速に成長すると予想されます。精神疾患に関する啓蒙活動の高まりと精神疾患の有病率の上昇が、同地域全体の市場需要を大きく促進しています。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を定義し、今後数年間の値を予測することです。本レポートは、調査対象国における産業の質的・量的側面を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

第2章 抗精神病薬の世界市場の定義と範囲

• 調査目的
• 市場の定義と範囲
  • 産業の進化
  • 調査範囲
• 調査対象年
• 通貨換算レート

第3章 抗精神病薬の世界市場力学

• 抗精神病薬市場の影響分析（2020年～2030年）
  • 市場促進要因
    • メンタルヘルスに焦点を当てた啓発プログラムの増加
    • 精神疾患の有病率の上昇
  • 市場の課題
    • 抗精神病薬に伴う副作用
    • メンタルヘルス・プログラムのコスト上昇
  • 市場機会
    • 長時間作用型注射剤（LAI）の採用増加
    • 新規抗精神病薬開発のための研究開発イニシアチブの高まり

第4章 抗精神病薬の世界市場産業分析

• ポーターのファイブフォースモデル
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• ポーターのファイブフォース影響分析
• PEST分析
  • 政治的
  • 経済
  • 社会
  • 技術
  • 環境
  • 法律
• 主な投資機会
• 主要成功戦略
• COVID-19影響分析
• 破壊的動向
• 業界専門家の視点
• アナリストの結論・提言

第5章 抗精神病薬の世界市場：疾患別

• 市場スナップショット
• 抗精神病薬の世界市場：疾患別、実績 - ポテンシャル分析
• 抗精神病薬の世界市場：疾患別推定・予測、2020年～2030年
• 抗精神病薬市場、サブセグメント分析
  • 統合失調症
  • 双極性障害
  • 単極性うつ病
  • 認知症
  • その他

第6章 抗精神病薬の世界市場：薬剤別

• 市場スナップショット
• 抗精神病薬の世界市場：薬剤別、実績 - ポテンシャル分析
• 抗精神病薬の世界市場：薬剤別推定・予測、2020年～2030年
• 抗精神病薬市場、サブセグメント別分析
  • リスペリドン
  • クエチアピン
  • オランザピン
  • アリピプラゾール
  • ブレクスピプラゾール
  • パルミチン酸パリペリドン
  • その他

第7章 抗精神病薬の世界市場：薬剤クラス別

• 市場スナップショット
• 抗精神病薬の世界市場：治療クラス別、実績 - ポテンシャル分析
• 抗精神病薬の世界市場：治療クラス別推定・予測、2020年～2030年
• 抗精神病薬市場、サブセグメント分析
  • 第一世代
  • 第二世代
  • 第三世代

第8章 抗精神病薬市場：流通チャネル別

• 市場スナップショット
• 抗精神病薬の世界市場：流通チャネル別、実績 - ポテンシャル分析
• 抗精神病薬の世界市場：流通チャネル別推定・予測、2020年～2030年
• 抗精神病薬市場、サブセグメント分析
  • 病院薬局
  • ドラッグストア・小売薬局
  • オンライン薬局

第9章 抗精神病薬の世界市場：地域別分析

• 主要国
• 主な新興国
• 抗精神病薬市場、地域別市場スナップショット
• 北米
  • 米国
    • 疾患の推定・予測、2020年～2030年
    • 薬剤別の推定・予測、2020年～2030年
    • 薬剤クラス別の推定・予測、2020年～2030年
    • 流通チャネルの推定・予測、2020年～2030年
  • カナダ
• 欧州の抗精神病薬市場スナップショット
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • その他の欧州
• アジア太平洋の抗精神病薬市場スナップショット
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他のアジア太平洋
• ラテンアメリカの抗精神病薬市場スナップショット
  • ブラジル
  • メキシコ
• 中東・アフリカ
  • サウジアラビア
  • 南アフリカ
  • その他の中東・アフリカ

第10章 競合情報

• 主要企業のSWOT分析
• 主要市場戦略
• 企業プロファイル
  • H. Lundbeck A/S (Denmark)
    • 主要情報
    • 概要
    • 財務（データの入手が可能な場合のみ）
    • 製品概要
    • 最近の動向
  • Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Janssen Pharmaceuticals, Inc. (Johnson & Johnson) (Belgium)
  • Eli Lilly and Company (U.S.)
  • ALLERGAN (AbbVie, Inc.) (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Dr. Reddy's Laboratories Ltd. (India)
  • Sumitomo Dainippon Pharma Co., Ltd. (Japan)
  • Alkermes plc (Ireland)
  • Bristol-Myers Squibb Company (U.S.)

第11章 調査プロセス

• 調査プロセス
  • データマイニング
  • 分析
  • 市場推定
  • 検証
  • 出版
• 調査属性
• 調査前提条件

LIST OF TABLES

• TABLE 1.Global Antipsychotic Drugs Market, report scope
• TABLE 2.Global Antipsychotic Drugs Market estimates & forecasts by Region 2020-2030 (USD Billion)
• TABLE 3.Global Antipsychotic Drugs Market estimates & forecasts by Disease 2020-2030 (USD Billion)
• TABLE 4.Global Antipsychotic Drugs Market estimates & forecasts by Drug 2020-2030 (USD Billion)
• TABLE 5.Global Antipsychotic Drugs Market estimates & forecasts by Therapeutic Class 2020-2030 (USD Billion)
• TABLE 6.Global Antipsychotic Drugs Market estimates & forecasts by Distribution Channel 2020-2030 (USD Billion)
• TABLE 7.Global Antipsychotic Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 8.Global Antipsychotic Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 9.Global Antipsychotic Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 10.Global Antipsychotic Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 11.Global Antipsychotic Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 12.Global Antipsychotic Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 13.Global Antipsychotic Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 14.Global Antipsychotic Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 15.Global Antipsychotic Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 16.Global Antipsychotic Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 17.U.S. Antipsychotic Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 18.U.S. Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 19.U.S. Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 20.Canada Antipsychotic Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 21.Canada Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 22.Canada Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 23.UK Antipsychotic Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 24.UK Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 25.UK Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 26.Germany Antipsychotic Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 27.Germany Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 28.Germany Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 29.France Antipsychotic Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 30.France Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 31.France Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 32.Italy Antipsychotic Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 33.Italy Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 34.Italy Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 35.Spain Antipsychotic Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 36.Spain Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 37.Spain Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 38.RoE Antipsychotic Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 39.RoE Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 40.RoE Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 41.China Antipsychotic Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 42.China Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 43.China Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 44.India Antipsychotic Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 45.India Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 46.India Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 47.Japan Antipsychotic Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 48.Japan Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 49.Japan Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 50.South Korea Antipsychotic Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 51.South Korea Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 52.South Korea Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 53.Australia Antipsychotic Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 54.Australia Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 55.Australia Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 56.RoAPAC Antipsychotic Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 57.RoAPAC Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 58.RoAPAC Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 59.Brazil Antipsychotic Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 60.Brazil Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 61.Brazil Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 62.Mexico Antipsychotic Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 63.Mexico Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 64.Mexico Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 65.RoLA Antipsychotic Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 66.RoLA Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 67.RoLA Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 68.Saudi Arabia Antipsychotic Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 69.South Africa Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 70.RoMEA Antipsychotic Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 71.List of secondary sources, used in the study of global Antipsychotic Drugs Market
• TABLE 72.List of primary sources, used in the study of global Antipsychotic Drugs Market
• TABLE 73.Years considered for the study
• TABLE 74.Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

• FIG 1.Global Antipsychotic Drugs Market, research methodology
• FIG 2.Global Antipsychotic Drugs Market, Market estimation techniques
• FIG 3.Global Market size estimates & forecast methods
• FIG 4.Global Antipsychotic Drugs Market, key trends 2022
• FIG 5.Global Antipsychotic Drugs Market, growth prospects 2023-2030
• FIG 6.Global Antipsychotic Drugs Market, porters 5 force model
• FIG 7.Global Antipsychotic Drugs Market, pest analysis
• FIG 8.Global Antipsychotic Drugs Market, value chain analysis
• FIG 9.Global Antipsychotic Drugs Market by segment, 2020 & 2030 (USD Billion)
• FIG 10.Global Antipsychotic Drugs Market by segment, 2020 & 2030 (USD Billion)
• FIG 11.Global Antipsychotic Drugs Market by segment, 2020 & 2030 (USD Billion)
• FIG 12.Global Antipsychotic Drugs Market by segment, 2020 & 2030 (USD Billion)
• FIG 13.Global Antipsychotic Drugs Market by segment, 2020 & 2030 (USD Billion)
• FIG 14.Global Antipsychotic Drugs Market, regional snapshot 2020 & 2030
• FIG 15.North America Antipsychotic Drugs Market 2020 & 2030 (USD Billion)
• FIG 16.Europe Antipsychotic Drugs Market 2020 & 2030 (USD Billion)
• FIG 17.Asia pacific Antipsychotic Drugs Market 2020 & 2030 (USD Billion)
• FIG 18.Latin America Antipsychotic Drugs Market 2020 & 2030 (USD Billion)
• FIG 19.Middle East & Africa Antipsychotic Drugs Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

Global Antipsychotic Drugs Market is valued approximately at USD 15.47 billion in 2022 and is anticipated to grow with a growth rate of more than 6% over the forecast period 2023-2030. Antipsychotic drugs are medications used to manage symptoms of psychotic disorders like schizophrenia and bipolar disorder. They work by altering neurotransmitter activity in the brain, particularly dopamine and serotonin. There are two main types: first-generation (typical) and second-generation (atypical) antipsychotics. First-generation drugs such as chlorpromazine primarily block dopamine receptors, while second-generation medications like risperidone affect both dopamine and serotonin receptors. Second-generation antipsychotics are preferred due to their reduced risk of movement disorders. These medications are prescribed based on the severity of symptoms and individual response, with close monitoring to manage side effects. The surge in mental disorder prevalence, the expanding geriatric demographic, shifting preference towards atypical antipsychotics, and rising awareness programs focusing on mental health collectively fuel market expansion for antipsychotic drugs across the globe. Additionally, the growing emphasis on education and advocacy aimed at reducing stigma and promoting human rights further propels growth within the global antipsychotic drugs market.

In addition, the rise in prevalence of mental health disorders to propel market expansion globally.

This surge in the global patient population is anticipated to fuel market growth significantly. For instance, a 2022 article published by the World Health Organization (WHO) projected that mental disorders could impose an estimated USD 6.0 trillion burden on the global economy by 2030. Such statistics are anticipated to stimulate the demand for these therapeutics as awareness regarding the severity of mental illnesses continues to increase. According to WHO estimates from 2022, approximately 970.0 million individuals globally, or about 1 in every eight people, were living with mental disorders such as anxiety and depression in 2019. However, in recent years, there has been a rise in the prevalence of schizophrenia and bipolar disorder. Consequently, several pharmaceutical companies have intensified their research and development efforts in this domain, leading to the introduction of new products in the forecast period. These factors are poised to drive substantial global market growth in the coming years. Moreover, the rise in the adoption of Long-Acting Injectables (LAIs), as well as the growing R&D initiatives for the development of novel antipsychotic drugs presents various lucrative opportunities over the forecasting years. However, the several side effects associated with antipsychotic drugs and the rise in cost of mental health programs are hindering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Antipsychotic Drugs Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 with largest market share owing to the high prevalence of psychiatric disorders and the presence of leading biopharmaceutical companies. According to the 2022 report from the National Alliance on Mental Illness (NAMI), the annual prevalence of bipolar disorder in the U.S. is 2.8%, affecting an estimated 7 million individuals. Additionally, the region's strong adoption of technologically advanced antipsychotics contributes significantly to its market position. Moreover, robust awareness campaigns highlighting the severity of mental illnesses are expected to further propel market growth in North America throughout the forecast period. Whereas, Asia Pacific is expected to grow the fastest over the forecast years. The rising awareness campaigns about psychiatric disorders and the rising prevalence of mental health conditions are significantly propelling the market demand across the region.

Major market players included in this report are:

• H. Lundbeck A/S (Denmark)
• Otsuka Pharmaceutical Co., Ltd. (Japan)
• Janssen Pharmaceuticals, Inc. (Johnson & Johnson) (Belgium)
• Eli Lilly and Company (U.S.)
• ALLERGAN (AbbVie, Inc.) (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Dr. Reddy's Laboratories Ltd. (India)
• Sumitomo Dainippon Pharma Co., Ltd. (Japan)
• Alkermes plc (Ireland)
• Bristol-Myers Squibb Company (U.S.)

Recent Developments in the Market:

• In February 2023, Lupin introduced a generic antipsychotic medication in the United States, available in strengths of 20, 40, 60, 80, and 120 mg. This generic variant mirrors Sunovion Pharmaceuticals Inc.'s Latuda tablets.
• In March 2022, AbbVie initiated a co-development and licensing partnership with Gedeon Richter Plc. This collaboration aims to research, develop, and commercialize dopamine receptor modulators intended for the potential treatment of neuropsychiatric diseases.
• In February 2022, Alkermes plc reported favorable outcomes from ENLIGHTEN-Early, a phase 3b study examining the impact of LYBALVI (olanzapine and samidorphan) in comparison to olanzapine on body weight in young adult patients aged 16 to 39, with diagnoses of schizophrenia, schizophreniform disorder, or bipolar I disorder (mean age: 26 years).
• In January 2022, Otsuka America Pharmaceutical, Inc. and H. Lundbeck A/S secured approval from the U.S. FDA for the supplemental new drug application (sNDA) of REXULTI (brexpiprazole) for the treatment of schizophrenia in patients aged 13 to 17 years.

Global Antipsychotic Drugs Market Report Scope:

• Historical Data - 2020 - 2021
• Base Year for Estimation - 2022
• Forecast period - 2023-2030
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered - Disease, Drug, Therapeutic Class, Distribution Channel, Region
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Disease:

• Schizophrenia
• Bipolar Disorder
• Unipolar Depression
• Dementia
• Others

By Drug:

• Risperidone
• Quetiapine
• Olanzapine
• Aripiprazole
• Brexpiprazole
• Paliperidone Palmitate
• Others

By Therapeutic Class:

• First Generation
• Second Generation
• Third Generation

By Distribution Channel:

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1.Executive Summary

• 1.1.Market Snapshot
• 1.2.Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1.Antipsychotic Drugs Market, by region, 2020-2030 (USD Billion)
  • 1.2.2.Antipsychotic Drugs Market, by Disease, 2020-2030 (USD Billion)
  • 1.2.3.Antipsychotic Drugs Market, by Drug, 2020-2030 (USD Billion)
  • 1.2.4.Antipsychotic Drugs Market, by Therapeutic Class, 2020-2030 (USD Billion)
  • 1.2.5.Antipsychotic Drugs Market, by Distribution Channel, 2020-2030 (USD Billion)
• 1.3.Key Trends
• 1.4.Estimation Methodology
• 1.5.Research Assumption

Chapter 2.Global Antipsychotic Drugs Market Definition and Scope

• 2.1.Objective of the Study
• 2.2.Market Definition & Scope
  • 2.2.1.Industry Evolution
  • 2.2.2.Scope of the Study
• 2.3.Years Considered for the Study
• 2.4.Currency Conversion Rates

Chapter 3.Global Antipsychotic Drugs Market Dynamics

• 3.1.Antipsychotic Drugs Market Impact Analysis (2020-2030)
  • 3.1.1.Market Drivers
    • 3.1.1.1.Increasing number of awareness programs focusing on mental health
    • 3.1.1.2.Rising prevalence of mental health disorders
  • 3.1.2.Market Challenges
    • 3.1.2.1.Side effects associated with antipsychotic drugs
    • 3.1.2.2.Rise in cost of mental health programs
  • 3.1.3.Market Opportunities
    • 3.1.3.1.Rise in the adoption of Long-Acting Injectables (LAIs)
    • 3.1.3.2.Growing R&D initiatives for development of novel antipsychotic drugs

Chapter 4.Global Antipsychotic Drugs Market: Industry Analysis

• 4.1.Porter's 5 Force Model
  • 4.1.1.Bargaining Power of Suppliers
  • 4.1.2.Bargaining Power of Buyers
  • 4.1.3.Threat of New Entrants
  • 4.1.4.Threat of Substitutes
  • 4.1.5.Competitive Rivalry
• 4.2.Porter's 5 Force Impact Analysis
• 4.3.PEST Analysis
  • 4.3.1.Political
  • 4.3.2.Economic
  • 4.3.3.Social
  • 4.3.4.Technological
  • 4.3.5.Environmental
  • 4.3.6.Legal
• 4.4.Top investment opportunity
• 4.5.Top winning strategies
• 4.6.COVID-19 Impact Analysis
• 4.7.Disruptive Trends
• 4.8.Industry Expert Perspective
• 4.9.Analyst Recommendation & Conclusion

Chapter 5.Global Antipsychotic Drugs Market, by Disease

• 5.1.Market Snapshot
• 5.2.Global Antipsychotic Drugs Market by Disease, Performance - Potential Analysis
• 5.3.Global Antipsychotic Drugs Market Estimates & Forecasts by Disease 2020-2030 (USD Billion)
• 5.4.Antipsychotic Drugs Market, Sub Segment Analysis
  • 5.4.1.Schizophrenia
  • 5.4.2.Bipolar Disorder
  • 5.4.3.Unipolar Depression
  • 5.4.4.Dementia
  • 5.4.5.Others

Chapter 6.Global Antipsychotic Drugs Market, by Drug

• 6.1.Market Snapshot
• 6.2.Global Antipsychotic Drugs Market by Drug, Performance - Potential Analysis
• 6.3.Global Antipsychotic Drugs Market Estimates & Forecasts by Drug 2020-2030 (USD Billion)
• 6.4.Antipsychotic Drugs Market, Sub Segment Analysis
  • 6.4.1.Risperidone
  • 6.4.2.Quetiapine
  • 6.4.3.Olanzapine
  • 6.4.4.Aripiprazole
  • 6.4.5.Brexpiprazole
  • 6.4.6.Paliperidone Palmitate
  • 6.4.7.Others

Chapter 7.Global Antipsychotic Drugs Market, by Therapeutic Class

• 7.1.Market Snapshot
• 7.2.Global Antipsychotic Drugs Market by Therapeutic Class, Performance - Potential Analysis
• 7.3.Global Antipsychotic Drugs Market Estimates & Forecasts by Therapeutic Class 2020-2030 (USD Billion)
• 7.4.Antipsychotic Drugs Market, Sub Segment Analysis
  • 7.4.1.First Generation
  • 7.4.2.Second Generation
  • 7.4.3.Third Generation

Chapter 8.Antipsychotic Drugs Market, by Distribution Channel

• 8.1.Market Snapshot
• 8.2.Global Antipsychotic Drugs Market by Distribution Channel, Performance - Potential Analysis
• 8.3.Global Antipsychotic Drugs Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
• 8.4.Antipsychotic Drugs Market, Sub Segment Analysis
  • 8.4.1.Hospital Pharmacies
  • 8.4.2.Drug Stores & Retail Pharmacies
  • 8.4.3.Online Pharmacies

Chapter 9.Global Antipsychotic Drugs Market, Regional Analysis

• 9.1.Top Leading Countries
• 9.2.Top Emerging Countries
• 9.3.Antipsychotic Drugs Market, Regional Market Snapshot
• 9.4.North America Antipsychotic Drugs Market
  • 9.4.1.U.S. Antipsychotic Drugs Market
    • 9.4.1.1.Disease breakdown estimates & forecasts, 2020-2030
    • 9.4.1.2.Drug breakdown estimates & forecasts, 2020-2030
    • 9.4.1.3.Therapeutic Class breakdown estimates & forecasts, 2020-2030
    • 9.4.1.4.Distribution Channel breakdown estimates & forecasts, 2020-2030
  • 9.4.2.Canada Antipsychotic Drugs Market
• 9.5.Europe Antipsychotic Drugs Market Snapshot
  • 9.5.1.U.K. Antipsychotic Drugs Market
  • 9.5.2.Germany Antipsychotic Drugs Market
  • 9.5.3.France Antipsychotic Drugs Market
  • 9.5.4.Spain Antipsychotic Drugs Market
  • 9.5.5.Italy Antipsychotic Drugs Market
  • 9.5.6.Rest of Europe Antipsychotic Drugs Market
• 9.6.Asia-Pacific Antipsychotic Drugs Market Snapshot
  • 9.6.1.China Antipsychotic Drugs Market
  • 9.6.2.India Antipsychotic Drugs Market
  • 9.6.3.Japan Antipsychotic Drugs Market
  • 9.6.4.Australia Antipsychotic Drugs Market
  • 9.6.5.South Korea Antipsychotic Drugs Market
  • 9.6.6.Rest of Asia Pacific Antipsychotic Drugs Market
• 9.7.Latin America Antipsychotic Drugs Market Snapshot
  • 9.7.1.Brazil Antipsychotic Drugs Market
  • 9.7.2.Mexico Antipsychotic Drugs Market
• 9.8.Middle East & Africa Antipsychotic Drugs Market
  • 9.8.1.Saudi Arabia Antipsychotic Drugs Market
  • 9.8.2.South Africa Antipsychotic Drugs Market
  • 9.8.3.Rest of Middle East & Africa Antipsychotic Drugs Market

Chapter 10.Competitive Intelligence

• 10.1.Key Company SWOT Analysis
• 10.2.Top Market Strategies
• 10.3.Company Profiles
  • 10.3.1.H. Lundbeck A/S (Denmark)
    • 10.3.1.1.Key Information
    • 10.3.1.2.Overview
    • 10.3.1.3.Financial (Subject to Data Availability)
    • 10.3.1.4.Product Summary
    • 10.3.1.5.Recent Developments
  • 10.3.2.Otsuka Pharmaceutical Co., Ltd. (Japan)
  • 10.3.3.Janssen Pharmaceuticals, Inc. (Johnson & Johnson) (Belgium)
  • 10.3.4.Eli Lilly and Company (U.S.)
  • 10.3.5.ALLERGAN (AbbVie, Inc.) (U.S.)
  • 10.3.6.Teva Pharmaceutical Industries Ltd. (Israel)
  • 10.3.7.Dr. Reddy's Laboratories Ltd. (India)
  • 10.3.8.Sumitomo Dainippon Pharma Co., Ltd. (Japan)
  • 10.3.9.Alkermes plc (Ireland)
  • 10.3.10.Bristol-Myers Squibb Company (U.S.)

Chapter 11.Research Process

• 11.1.Research Process
  • 11.1.1.Data Mining
  • 11.1.2.Analysis
  • 11.1.3.Market Estimation
  • 11.1.4.Validation
  • 11.1.5.Publishing
• 11.2.Research Attributes
• 11.3.Research Assumption